US cost-utility model of lenacapavir plus optimized background regimen (OBR) vs fostemsavir plus OBR and ibalizumab plus OBR for people with HIV with multidrug resistance

Lenacapavir is a treatment for people living with HIV who have become resistant to several other HIV medications. This study looked at how well treatment with lenacapavir works and how much it costs to treat someone with lenacapavir compared with other treatments. The results suggest that treating t...

Full description

Saved in:
Bibliographic Details
Published in:Journal of managed care & specialty pharmacy 2024-09, Vol.30 (9), p.1001-1012
Main Authors: Vardanega, Vittoria, New, Emma, Mezzio, Dylan, Eddowes, Lucy A.
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lenacapavir is a treatment for people living with HIV who have become resistant to several other HIV medications. This study looked at how well treatment with lenacapavir works and how much it costs to treat someone with lenacapavir compared with other treatments. The results suggest that treating these individuals with lenacapavir is good value for money compared with other treatments currently available in the United States. This study found that lenacapavir in combination with an optimized background regimen (OBR) is associated with lower lifetime costs and improved health outcomes compared with 2 alternative HIV treatments (fostemsavir plus OBR and ibalizumab plus OBR), when assessed from a US health care payer perspective. Lenacapavir plus OBR is therefore a promising treatment choice for heavily treatment-experienced people with HIV, beneficial for individuals and health care payers. This pharmacoeconomic evaluation can aid formulary decision-making in managed care.
ISSN:2376-0540
2376-1032
DOI:10.18553/jmcp.2024.30.9.1001